Prestige Consumer Healthcare (NYSE:PBH) Updates FY25 Earnings Guidance

Prestige Consumer Healthcare (NYSE:PBH) updated its FY25 earnings guidance on Thursday. The company provided earnings per share guidance of $4.40-4.46 for the period, compared to the consensus earnings per share estimate of $4.40. The company issued revenue guidance of $1.13-1.14 billion, compared to the consensus revenue estimate of $1.13 billion. Prestige Consumer Healthcare also updated its FY 2025 guidance to 4.400-4.460 EPS.

Wall Street Analysts Forecast Growth

PBH has been the subject of several recent analyst reports. DA Davidson reaffirmed a buy rating and issued a $93.00 price target on shares of Prestige Consumer Healthcare in a research report on Friday. StockNews.com lowered Prestige Consumer Healthcare from a strong-buy rating to a buy rating in a research report on Tuesday, May 21st. Finally, Canaccord Genuity Group reaffirmed a buy rating and issued a $80.00 price target on shares of Prestige Consumer Healthcare in a research report on Tuesday, May 21st. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of Moderate Buy and an average price target of $98.25.

Prestige Consumer Healthcare Stock Performance

NYSE PBH traded down $0.59 during trading hours on Friday, hitting $66.25. The company’s stock had a trading volume of 274,252 shares, compared to its average volume of 250,556. Prestige Consumer Healthcare has a 12 month low of $56.34 and a 12 month high of $75.31. The company’s 50 day simple moving average is $68.20 and its two-hundred day simple moving average is $68.51. The company has a market cap of $3.29 billion, a P/E ratio of 15.89, a price-to-earnings-growth ratio of 2.00 and a beta of 0.49. The company has a debt-to-equity ratio of 0.68, a current ratio of 3.20 and a quick ratio of 2.02.

Prestige Consumer Healthcare (NYSE:PBH) last released its quarterly earnings data on Thursday, August 8th. The company reported $0.90 EPS for the quarter, topping the consensus estimate of $0.86 by $0.04. Prestige Consumer Healthcare had a return on equity of 13.48% and a net margin of 18.60%. The company had revenue of $267.10 million during the quarter, compared to the consensus estimate of $260.54 million. During the same period last year, the company earned $1.06 EPS. Prestige Consumer Healthcare’s revenue for the quarter was down 4.4% on a year-over-year basis. As a group, sell-side analysts expect that Prestige Consumer Healthcare will post 4.42 EPS for the current fiscal year.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.